Skip to main content

Intraocular Inflammation More Common With Aflibercept Injections in Real-World Setting

By Lori Solomon HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on May 9, 2025.

via HealthDay

FRIDAY, May 9, 2025 -- The incidence of mild intraocular inflammation (IOI) in the real world occurs more frequently after intravitreal injection of aflibercept than in clinical trials, according to a study published online May 1 in JAMA Ophthalmology.

Karoline E. Binder, M.D., from the Technical University of Munich, and colleagues assessed the incidence of IOI after intravitreal injection of aflibercept, 8 mg, in real-world practice. The analysis included 41 patients (23 with neovascular age-related macular degeneration and 18 with diabetic macular edema) who were treated with 136 intravitreal aflibercept, 8 mg, injections.

The researchers reported that five patients developed mild sterile IOI within one to three days after the intervention (incidence per injection, 3.7 percent; incidence per patient, 12 percent). Only one patient developed inflammation after the first dose, while the other four had prior exposure to aflibercept. All patients were treated with local anti-inflammatory therapy (topical or subconjunctival corticosteroids), while two patients received additional systemic oral corticosteroids. After IOI resolved, there was no reduction in best-corrected visual acuity.

"Although the IOI found in this series can be considered mild, careful evaluation of patient-associated risk factors and thorough patient education are warranted," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Semaglutide Not Linked to Increased Risk of Eye Disorders, Diabetic Retinopathy

MONDAY, Aug. 18, 2025 -- For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy, according to a review...

GLP-1 Receptor Agonists May Reduce Complications of Diabetic Retinopathy

TUESDAY, Aug. 12, 2025 -- For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for...

ENDO: AI Model Integrated Into Retina Tracker IDs Diabetic Retinopathy

FRIDAY, July 18, 2025 -- An artificial intelligence (AI) model integrated into a retina tracker for diabetic retinopathy can achieve high accuracy while being resource-efficient...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.